A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2)
Latest Information Update: 23 Oct 2026
At a glance
- Drugs WVE-006 (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions
- Acronyms RestorAATion; RestorAATion 2
- Sponsors WaVe life Sciences
Most Recent Events
- 19 Oct 2026 Planned number of patients changed from 24 to 48.
- 19 Oct 2026 Planned End Date changed from 1 Sep 2026 to 1 Sep 2027.
- 19 Oct 2026 Planned primary completion date changed from 1 Sep 2026 to 1 Sep 2027.